United States – Pfizer (PFE. N) on Monday said that its respiratory syncytial virus (RSV) vaccine Abrysvo demonstrated robust immune response in the final trial of four groups of adults aged 18 and above with weakened immune systems. Strong Antibody ...
United States – The FDA law has recently accredited the use of an RSV vaccine not only to infants but to at-risk adults over the age of 50 years. It comes a day after manufacturer GSK stated the approval on ...